10-Q Filing

ACCELERATE DIAGNOSTICS, INC CIK: 727207 Q1 2011

Filing Information

Form Type	10-Q
Accession Number	`0001000096-11-000304`
Period End Date	20111031
Filing Date	20111214
Fiscal Year	2011
Fiscal Period	Q1
XBRL Instance	axk-20111031.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 56 Income Statement 36 Cash Flow Statement 44

Balance Sheet 56 line items

Line Item	Tag	Value	Unit	Period
Common Stock, no par value;	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Common Stock, no par value;	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	19.00M	shares	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	19.00M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	11.10M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$283.27K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$222.49K	USD	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	11.10M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$775.86K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$584.99K	USD	Point-in-time
Common Stock, outstanding	`CommonStockSharesOutstanding`	11.10M	shares	Point-in-time
Trade Accounts Receivable	`ReceivablesNetCurrent`	$760.73K	USD	Point-in-time
Trade Accounts Receivable	`ReceivablesNetCurrent`	$596.13K	USD	Point-in-time
Common Stock, outstanding	`CommonStockSharesOutstanding`	11.10M	shares	Point-in-time
Shares held for employee benefit	`DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital`	$1.13M	USD	Point-in-time
Inventory	`InventoryNet`	$30.28K	USD	Point-in-time
Inventory	`InventoryNet`	$30.28K	USD	Point-in-time
Shares held for employee benefit	`DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital`	$1.13M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$20.58K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$10.75K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.42M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.39M	USD	Point-in-time
Long Term Accounts Receivable, Net of current portion	`LongTermInvestmentsAndReceivablesNet`	$745.44K	USD	Point-in-time
Long Term Accounts Receivable, Net of current portion	`LongTermInvestmentsAndReceivablesNet`	$746.59K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$3.53K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$3.01K	USD	Point-in-time
Investments, net	`Goodwill`	$1.38M	USD	Point-in-time
Investments, net	`Goodwill`	$1.30M	USD	Point-in-time
Intellectual property, net	`FiniteLivedIntangibleAssetsNet`	$2.79M	USD	Point-in-time
Intellectual property, net	`FiniteLivedIntangibleAssetsNet`	$2.74M	USD	Point-in-time
Total assets	`Assets`	$6.26M	USD	Point-in-time
Total assets	`Assets`	$6.25M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$56.69K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$34.96K	USD	Point-in-time
Accrued compensation and other liabilities	`EmployeeRelatedLiabilitiesCurrent`	$36.08K	USD	Point-in-time
Accrued compensation and other liabilities	`EmployeeRelatedLiabilitiesCurrent`	$24.58K	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$105.28K	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$9.80K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$69.34K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$198.04K	USD	Point-in-time
Deferred compensation	`DeferredCompensationLiabilityCurrent`	$1.40M	USD	Point-in-time
Deferred compensation	`DeferredCompensationLiabilityCurrent`	$1.38M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.59M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.45M	USD	Point-in-time
Common Stock, no par value; 19,000,000 shares authorized; 11,103,367 shares issued and outstanding	`CommonStockNoParValue`	$14.33M	USD	Point-in-time
Common Stock, no par value; 19,000,000 shares authorized; 11,103,367 shares issued and outstanding	`CommonStockNoParValue`	$14.33M	USD	Point-in-time
Contributed capital	`AdditionalPaidInCapitalCommonStock`	$1.52M	USD	Point-in-time
Contributed capital	`AdditionalPaidInCapitalCommonStock`	$1.25M	USD	Point-in-time
Accumulated (deficit)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-10.49M	USD	Point-in-time
Accumulated (deficit)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-10.92M	USD	Point-in-time
Shares held for employee benefit (1,129,110 shares at cost)	`SharesHeldInEmployeeStockOptionPlanAllocated`	-273,600.00	shares	Point-in-time
Shares held for employee benefit (1,129,110 shares at cost)	`SharesHeldInEmployeeStockOptionPlanAllocated`	-273,600.00	shares	Point-in-time
Total Shareholders' equity	`StockholdersEquity`	$4.66M	USD	Point-in-time
Total Shareholders' equity	`StockholdersEquity`	$4.82M	USD	Point-in-time
Total liabilities and Shareholders' equity	`LiabilitiesAndStockholdersEquity`	$6.26M	USD	Point-in-time
Total liabilities and Shareholders' equity	`LiabilitiesAndStockholdersEquity`	$6.25M	USD	Point-in-time

Income Statement 36 line items

Line Item	Tag	Value	Unit	Period
OptiChem(R) revenues	`LicensesRevenue`	$11.88K	USD	1 Quarter
OptiChem(R) revenues	`LicensesRevenue`	$12.01K	USD	1 Quarter
Technical Development Fees	`ProfessionalAndContractServicesExpense`	$-140.00K	USD	1 Quarter
Technical Development Fees	`ProfessionalAndContractServicesExpense`	$-210.00K	USD	1 Quarter
Product Licensing Fees	`CostOfServicesLicensesAndServices`	$-50.00K	USD	1 Quarter
Product Licensing Fees	`CostOfServicesLicensesAndServices`	-	USD	1 Quarter
Qualified Therapeutic Discovery Grant	`RevenueFromGrants`	$244.48K	USD	1 Quarter
Qualified Therapeutic Discovery Grant	`RevenueFromGrants`	-	USD	1 Quarter
Total revenues	`SalesRevenueNet`	$466.36K	USD	1 Quarter
Total revenues	`SalesRevenueNet`	$202.01K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$104.16K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$111.05K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$458.98K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$235.57K	USD	1 Quarter
Amortization	`AmortizationOfIntangibleAssets`	$64.09K	USD	1 Quarter
Amortization	`AmortizationOfIntangibleAssets`	$63.18K	USD	1 Quarter
Marketing and sales	`SellingAndMarketingExpense`	$4.17K	USD	1 Quarter
Marketing and sales	`SellingAndMarketingExpense`	$5.99K	USD	1 Quarter
Depreciation	`DepreciationDepletionAndAmortization`	$599.00	USD	1 Quarter
Depreciation	`DepreciationDepletionAndAmortization`	$515.00	USD	1 Quarter
Total costs and expenses	`CostsAndExpenses`	$631.92K	USD	1 Quarter
Total costs and expenses	`CostsAndExpenses`	$416.39K	USD	1 Quarter
Income (Loss) from operations	`OperatingIncomeLoss`	$49.97K	USD	1 Quarter
Income (Loss) from operations	`OperatingIncomeLoss`	$-429.91K	USD	1 Quarter
Interest and dividend income	`OtherNonoperatingIncome`	$4.00K	USD	1 Quarter
Interest and dividend income	`OtherNonoperatingIncome`	$3.45K	USD	1 Quarter
Unrealized gain (loss) on investments	`UnrealizedGainLossOnInvestments`	$-4.37K	USD	1 Quarter
Unrealized gain (loss) on investments	`UnrealizedGainLossOnInvestments`	$13.83K	USD	1 Quarter
Total other income (loss)	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-365.00	USD	1 Quarter
Total other income (loss)	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$17.28K	USD	1 Quarter
Net Income( loss)	`NetIncomeLoss`	$67.25K	USD	1 Quarter
Net Income( loss)	`NetIncomeLoss`	$-430.27K	USD	1 Quarter
Basic and diluted net income (loss) per share	`EarningsPerShareBasicAndDiluted`	$-0.04	USD	1 Quarter
Basic and diluted net income (loss) per share	`EarningsPerShareBasicAndDiluted`	$0.01	USD	1 Quarter
Weighted average shares outstanding	`WeightedAverageNumberOfSharesOutstandingBasic`	11.10M	shares	1 Quarter
Weighted average shares outstanding	`WeightedAverageNumberOfSharesOutstandingBasic`	10.76M	shares	1 Quarter

Cash Flow Statement 44 line items

Line Item	Tag	Value	Unit	Period
Net Income (loss)	`NetIncomeLoss`	$67.25K	USD	1 Quarter
Net Income (loss)	`NetIncomeLoss`	$-430.27K	USD	1 Quarter
Depreciation	`Depreciation`	$599.00	USD	1 Quarter
Depreciation	`Depreciation`	$515.00	USD	1 Quarter
Amortization	`AmortizationOfIntangibleAssets`	$64.09K	USD	1 Quarter
Amortization	`AmortizationOfIntangibleAssets`	$63.18K	USD	1 Quarter
Fair value of stock options granted for services	`ShareBasedCompensation`	$272.53K	USD	1 Quarter
Fair value of stock options granted for services	`ShareBasedCompensation`	$8.65K	USD	1 Quarter
Unrealized holding (gain) loss on investments	`GainLossOnInvestments`	$-13.83K	USD	1 Quarter
Unrealized holding (gain) loss on investments	`GainLossOnInvestments`	$4.37K	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-165.75K	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-248.75K	USD	1 Quarter
Inventory	`IncreaseDecreaseInInventories`	$-300.00	USD	1 Quarter
Inventory	`IncreaseDecreaseInInventories`	-	USD	1 Quarter
Prepaid expense and other	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$8.34K	USD	1 Quarter
Prepaid expense and other	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$9.83K	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$32.04K	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$21.73K	USD	1 Quarter
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$11.50K	USD	1 Quarter
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$10.79K	USD	1 Quarter
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-4.08K	USD	1 Quarter
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$95.48K	USD	1 Quarter
Deferred compensation	`DeferredCompensationArrangementWithIndividualCompensationExpense`	$34.06K	USD	1 Quarter
Deferred compensation	`DeferredCompensationArrangementWithIndividualCompensationExpense`	$16.32K	USD	1 Quarter
Net cash (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-99.67K	USD	1 Quarter
Net cash (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-42.04K	USD	1 Quarter
Purchase Investments	`PaymentsToAcquireHeldToMaturitySecurities`	$-1.53K	USD	1 Quarter
Purchase Investments	`PaymentsToAcquireHeldToMaturitySecurities`	$-1.94K	USD	1 Quarter
Purchases of equipment and patent costs	`PaymentsToAcquirePropertyPlantAndEquipment`	$-17.21K	USD	1 Quarter
Purchases of equipment and patent costs	`PaymentsToAcquirePropertyPlantAndEquipment`	$-14.26K	USD	1 Quarter
Contribution to Deferred Compensation Trust	`AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition`	$-75.00K	USD	1 Quarter
Contribution to Deferred Compensation Trust	`AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition`	-	USD	1 Quarter
Net cash (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-91.20K	USD	1 Quarter
Net cash (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-18.74K	USD	1 Quarter
Decrease in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-190.87K	USD	1 Quarter
Decrease in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-60.78K	USD	1 Quarter
Beginning balance	`CashAndCashEquivalentsAtCarryingValue`	$283.27K	USD	Point-in-time
Beginning balance	`CashAndCashEquivalentsAtCarryingValue`	$222.49K	USD	Point-in-time
Beginning balance	`CashAndCashEquivalentsAtCarryingValue`	$775.86K	USD	Point-in-time
Beginning balance	`CashAndCashEquivalentsAtCarryingValue`	$584.99K	USD	Point-in-time
Ending balance	`CashAndCashEquivalentsAtCarryingValue`	$283.27K	USD	Point-in-time
Ending balance	`CashAndCashEquivalentsAtCarryingValue`	$222.49K	USD	Point-in-time
Ending balance	`CashAndCashEquivalentsAtCarryingValue`	$775.86K	USD	Point-in-time
Ending balance	`CashAndCashEquivalentsAtCarryingValue`	$584.99K	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.